NCT05846646终止2 期
Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered With or Without STING-Agonist IMSA101 in Patients With Oligometastatic NSCLC and RCC
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 6
- 试验地点
- 9
- 主要终点
- Anti-tumor Effects
研究概览
简要总结
Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy (PULSAR-ICI) + IMSA101 and PULSAR-ICI alone in patients with NSCLC or RCC
详细描述
Patients shall be enrolled in 2 treatment arms as follows:
- 20 patients in the control arm (PULSAR-ICI alone)
- 20 patients in the experimental arm (PULSAR-ICI + IMSA101)
Patients will be stratified by histology (NSCLC and RCC) in the randomized portion.
PULSAR-ICI with or without IMSA101 treatment will be administered to the patients in Cycles 1, 2, and 3, and thereafter only standard of care ICI monotherapy will be administered to all patients. Each treatment cycle will be 28 days in duration for Cycles 1, 2 and 3, then per standard of care monotherapy thereafter based on the product labels of the prescribed ICI.
The study will start with a safety run-in portion at 2 dose levels for the experimental arm, followed by a randomized portion for both treatment arms. The safety run-in shall employ a 3+3 safety run-in component.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients ≥ 18 years of age
- •Signed informed consent and mental capability to understand the informed consent
- •Histologically or cytologically documented NSCLC or RCC with radiographically documented presence of ≤ 6 metastatic lesions consistent with the diagnosis of "oligometastatic" disease
- •Patient's disease must be evaluable per RECIST Version 1.1
- •All metastatic lesions amenable to administration of radiotherapy, at the discretion of the investigator
- •Must have at least one single pre-defined lesion/lesion site (longest diameter ≥ 10 mm and ≤ 50 mm) suitable for intra-tumoral injection
- •Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
- •Electrocardiogram (ECG) without evidence of clinically significant conduction abnormalities or active ischemia as determined by the investigator
- •Acceptable organ and marrow function as defined below:
- •Absolute neutrophil count (ANC) > 1,500 cells/μL
- •Platelets > 50,000 cells/μL
- •Total bilirubin ≤ 1.5 times (×) the upper limit of normal (ULN)
- •Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 × ULN. If liver metastases are present, AST/ALT < 5 × ULN
- •Serum creatinine < 1.5 mg/dL and a measured creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault formula
- •Prothrombin time (PT)/partial thromboplastin time (PTT) ≤ 1.5 × ULN
- •Women of child-bearing potential (defined as a female who has experienced menarche and who has not undergone successful surgical sterilization [hysterectomy, bilateral salpingectomy, or bilateral oophorectomy]) or is not postmenopausal (defined as amenorrhea for at least 12 consecutive months with an appropriate clinical profile at the appropriate age, eg, greater than 45 years) must have a negative serum pregnancy test prior to first dose of study treatment
- •Male and female patients with reproductive potential must agree to use two forms of highly effective contraception throughout the study
排除标准
- •Prior disease progression through programmed cell death ligand 1 (PD-L1 or PD-1)-targeted immunotherapy
- •Prior receipt of stimulator of interferon genes (STING) agonist
- •Prior receipt of therapeutic radiotherapy to the lesions intended for PULSAR treatment
- •Anti-cancer therapy, except pembrolizumab and nivolumab, within 4 weeks or < 5 half-lives of the first dose of study treatment
- •Existence of primary tumor that requires therapeutic treatment beyond the provided immune checkpoint inhibitor drug
- •Failure to recover, to Grade 1 or less, from clinically significant AEs due to prior anti-cancer therapy, as judged by the investigator
- •Previous life-threatening (Grade 4) immune-related adverse event (irAE)
- •Existence of actionable mutations that may be eligible for mutation-targeted drug that represents standard-of-care therapy
- •Presence of brain metastases
- •Baseline prolongation of QT/corrected QT (QTc) interval (QTc interval > 470)
- •Uncontrolled intercurrent illness (including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations) that in the opinion of the investigator would limit compliance with study requirements
- •Women who are pregnant or breastfeeding
- •Sponsor reserves the right to exclude any patient from the study on the basis of pre-study medical histories, physical examination findings, clinical laboratory results, prior medications, or other entrance criteria
研究组 & 干预措施
Experimental Arm
Experimental
PULSAR-ICI + IMSA101
干预措施: IMSA101 (Drug)
Experimental Arm
Experimental
PULSAR-ICI + IMSA101
干预措施: Immune checkpoint inhibitor (Drug)
Experimental Arm
Experimental
PULSAR-ICI + IMSA101
干预措施: PULSAR (Radiation)
Control Arm
Active Comparator
PULSAR-ICI
干预措施: Immune checkpoint inhibitor (Drug)
Control Arm
Active Comparator
PULSAR-ICI
干预措施: PULSAR (Radiation)
结局指标
主要结局
Anti-tumor Effects
时间窗: 18 months
Progression-free rate at 18 months
次要结局
- Number of Participants With Treatment-related Adverse Events(Enrolment through end of study period (1 year, 3 months). AE data captured continually.)
- Anti-tumor Effects(upon enrolment through end of study period (2 years))
- Quality of Life (QoL)(upon enrolment through end of study period (2 years))
研究者
研究点 (9)
Loading locations...
相似试验
终止
2 期
Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor MalignanciesOligoprogressiveNCT05846659ImmuneSensor Therapeutics Inc.16
已完成
2 期
A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line TreatmentHepatocellular CarcinomaNCT01232296Novartis Pharmaceuticals162
进行中（未招募）
2 期
Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical CancerCervical CancerNCT03340376Universitaire Ziekenhuizen KU Leuven48
Unknown
2 期
Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast CancerBreast CancerNCT02842099Peking Union Medical College Hospital500
已完成
2 期
Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior TrastuzumabMetastatic Breast CancerNCT02338245ASLAN Pharmaceuticals200